Page 27 - Read Online

Ricci et al. Vessel Plus 2021;5:31 https://dx.doi.org/10.20517/2574-1209.2021.28 Page 13 of 14

1999;24:311-6. DOI PubMed
32. Béraud-Dufour S, Gautier R, Albiges-Rizo C, Chardin P, Faurobert E. Krit 1 interactions with microtubules and membranes are
regulated by Rap1 and integrin cytoplasmic domain associated protein-1. FEBS J 2007;274:5518-32. DOI PubMed PMC
33. Cavalcanti DD, Kalani MY, Martirosyan NL, Eales J, Spetzler RF, Preul MC. Cerebral cavernous malformations: from genes to
proteins to disease. J Neurosurg 2012;116:122-32. DOI PubMed
34. Verlaan DJ, Davenport WJ, Stefan H, Sure U, Siegel AM, Rouleau GA. Cerebral cavernous malformations: mutations in Krit1.
Neurology 2002;58:853-7. DOI PubMed
35. Maddaluno L, Rudini N, Cuttano R, et al. EndMT contributes to the onset and progression of cerebral cavernous malformations.
Nature 2013;498:492-6. DOI PubMed
36. Liquori CL, Berg MJ, Siegel AM, et al. Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain
cause type 2 cerebral cavernous malformations. Am J Hum Genet 2003;73:1459-64. DOI PubMed PMC
37. Fisher OS, Deng H, Liu D, et al. Structure and vascular function of MEKK3-cerebral cavernous malformations 2 complex. Nat
Commun 2015;6:7937. DOI PubMed PMC
38. Draheim KM, Li X, Zhang R, et al. CCM2-CCM3 interaction stabilizes their protein expression and permits endothelial network
formation. J Cell Biol 2015;208:987-1001. DOI PubMed PMC
39. Bergametti F, Viot G, Verny C, et al. Novel CCM2 missense variants abrogating the CCM1-CCM2 interaction cause cerebral
cavernous malformations. J Med Genet 2020;57:400-4. DOI PubMed
40. Zawistowski JS, Stalheim L, Uhlik MT, et al. CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral
cavernous malformations pathogenesis. Hum Mol Genet 2005;14:2521-31. DOI PubMed
41. Fisher OS, Liu W, Zhang R, et al. Structural basis for the disruption of the cerebral cavernous malformations 2 (CCM2) interaction
with Krev interaction trapped 1 (KRIT1) by disease-associated mutations. J Biol Chem 2015;290:2842-53. DOI PubMed PMC
42. Liquori CL, Berg MJ, Squitieri F, et al. Deletions in CCM2 are a common cause of cerebral cavernous malformations. Am J Hum
Genet 2007;80:69-75. DOI PubMed PMC
43. Hilder TL, Malone MH, Bencharit S, et al. Proteomic identification of the cerebral cavernous malformation signaling complex. J
Proteome Res 2007;6:4343-55. DOI PubMed
44. Li X, Zhang R, Zhang H, et al. Crystal structure of CCM3, a cerebral cavernous malformation protein critical for vascular integrity. J
Biol Chem 2010;285:24099-107. DOI PubMed PMC
45. He Y, Zhang H, Yu L, et al. Stabilization of VEGFR2 signaling by cerebral cavernous malformation 3 is critical for vascular
development. Sci Signal 2010;3:ra26. DOI PubMed PMC
46. Dibble CF, Horst JA, Malone MH, et al. Defining the functional domain of programmed cell death 10 through its interactions with
phosphatidylinositol-3,4,5-trisphosphate. PLoS One 2010;5:e11740. DOI PubMed PMC
47. You C, Sandalcioglu IE, Dammann P, Felbor U, Sure U, Zhu Y. Loss of CCM3 impairs DLL4-Notch signalling: implication in
endothelial angiogenesis and in inherited cerebral cavernous malformations. J Cell Mol Med 2013;17:407-18. DOI PubMed PMC
48. Wang Y, Liu H, Zhang Y, Ma D. cDNA cloning and expression of an apoptosis-related gene, humanTFAR15 gene. Sci China C Life
Sci 1999;42:323-9. DOI PubMed
49. Guclu B, Ozturk AK, Pricola KL, et al. Mutations in apoptosis-related gene, PDCD10, cause cerebral cavernous malformation 3.
Neurosurgery 2005;57:1008-13. DOI PubMed
50. Chen L, Tanriover G, Yano H, Friedlander R, Louvi A, Gunel M. Apoptotic functions of PDCD10/CCM3, the gene mutated in
cerebral cavernous malformation 3. Stroke 2009;40:1474-81. DOI PubMed PMC
51. Akers AL, Johnson E, Steinberg GK, Zabramski JM, Marchuk DA. Biallelic somatic and germline mutations in cerebral cavernous
malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet 2009;18:919-30. DOI PubMed
PMC
52. Gault J, Sain S, Hu LJ, Awad IA. Spectrum of genotype and clinical manifestations in cerebral cavernous malformations.
Neurosurgery 2006;59:1278-84; discussion 1284. DOI PubMed
53. Denier C, Labauge P, Brunereau L, et al; Sociéte Française de Neurochirgurgie. , Sociéte de Neurochirurgie de Langue Française.
Clinical features of cerebral cavernous malformations patients with KRIT1 mutations. Ann Neurol 2004;55:213-20. DOI PubMed
54. Denier C, Labauge P, Bergametti F, et al; Société Française de Neurochirurgie. Genotype-phenotype correlations in cerebral cavernous
malformations patients. Ann Neurol 2006;60:550-6. DOI PubMed
55. Riant F, Bergametti F, Fournier HD, et al. CCM3 Mutations are associated with early-onset cerebral hemorrhage and multiple
meningiomas. Mol Syndromol 2013;4:165-72. DOI PubMed PMC
56. Shenkar R, Shi C, Rebeiz T, et al. Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10
mutations. Genet Med 2015;17:188-96. DOI PubMed PMC
57. Gianfrancesco F, Cannella M, Martino T, et al. Highly variable penetrance in subjects affected with cavernous cerebral angiomas
(CCM) carrying novel CCM1 and CCM2 mutations. Am J Med Genet B Neuropsychiatr Genet 2007;144B:691-5. DOI PubMed
58. Craig HD, Günel M, Cepeda O, et al. Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous
malformation, at 7p15-13 and 3q25.2-27. Hum Mol Genet 1998;7:1851-8. DOI PubMed
59. Vos IJ, Vreeburg M, Koek GH, van Steensel MA. Review of familial cerebral cavernous malformations and report of seven additional
families. Am J Med Genet A 2017;173:338-51. DOI PubMed
60. Battistini S, Rocchi R, Cerase A, et al. Clinical, magnetic resonance imaging, and genetic study of 5 Italian families with cerebral
cavernous malformation. Arch Neurol 2007;64:843-8. DOI PubMed
61. Scimone C, Donato L, Katsarou Z, Bostantjopoulou S, D'Angelo R, Sidoti A. Two novel KRIT1 and CCM2 mutations in patients